| Biological Information | |
|---|---|
| Background Information: | N-terminal 6His-tagged recombinant, human full length BTK. Specific mutations within the pleckstrin homology (PH) domain of BTK results in human X-linked aγglobulinemia (XLA). The E41K substitution, identified through random mutagenesis, is a PH domain gain-of-function mutation that has been shown to be associated with increased membrane localization and tyrosine phosphorylation of BTK. Using animal models, this mutation has been shown to arrest the development of immature B cells and to act as a tumor suppressor in B-cell linker protein (BLNK/SLP-65)-deficient hosts. (Li, .et al., Immunity,(1995);2:451-460 and Baraldi, E., et al., Structure,(1999);7:449-460). |
| Target Class: | Kinase |
| Family: | Tyrosine Kinase: TEC Family |
| Accession Number: | NM_000061 |
| Target Name: | BTK |
| Target Aliases: | BTK, ATK, BPK, AGMX1 |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 6 months at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
BTK (E41K), active
10 µg of active BTK (E41K). N-terminal 6His-tagged recombinant, human full length BTK.
Datasheets
14-773x Datasheet
View Document